Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB)

Background Despite the great burden of chronic respiratory diseases in China, few large multicentre, spirometry-based studies have examined its prevalence, rate of underdiagnosis regionally or the relevance of socioeconomic and lifestyle factors. Methods We analysed data from 512 891 adults in the China Kadoorie Biobank, recruited from 10 diverse regions of China during 2004–2008. Air flow obstruction (AFO) was defined by the lower limit of normal criteria based on spirometry-measured lung function. The prevalence of AFO was analysed by region, age, socioeconomic status, body mass index (BMI) and smoking history and compared with the prevalence of self-reported physician-diagnosed chronic bronchitis or emphysema (CB/E) and its symptoms. Findings The prevalence of AFO was 7.3% in men (range 2.5–18.2%) and 6.4% in women (1.5–18.5%). Higher prevalence of AFO was associated with older age (p<0.0001), lower income (p<0.0001), poor education (p<0.001), living in rural regions (p<0.001), those who started smoking before the age of 20 years (p<0.001) and low BMI (p<0.001). Compared with self-reported diagnosis of CB/E, 88.8% of AFO was underdiagnosed; underdiagnosis proportion was highest in 30–39-year olds (96.7%) compared with the 70+ age group (81.1%), in women (90.7%), in urban areas (89.4%), in people earning 5K–10 K ¥ monthly (90.3%) and in those with middle or high school education (92.6%). Interpretation In China, the burden of AFO based on spirometry was high and significantly greater than that estimated based on self-reported physician-diagnosed CB/E, especially in rural areas, reflecting major issues with diagnosis of AFO that will impact disease treatment and management.

[1]  V. Barger International steering committee , 2020, 2012 14th International Conference on Megagauss Magnetic Field Generation and Related Topics (MEGAGAUSS).

[2]  Q. Yi,et al.  Association of chronic obstructive pulmonary disease with coronary artery disease , 2013, Chinese medical journal.

[3]  P. Calverley,et al.  Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. , 2013, The Lancet. Respiratory medicine.

[4]  S. Hurd,et al.  The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what? , 2012, The clinical respiratory journal.

[5]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[6]  T. To,et al.  Pulmonary function testing in the diagnosis of asthma: a population study. , 2012, Chest.

[7]  R. Collins,et al.  China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. , 2011, International journal of epidemiology.

[8]  J. Walters,et al.  Factors associated with misdiagnosis of COPD in primary care. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[9]  N. Zhong,et al.  Asymptomatic patients of chronic obstructive pulmonary disease in China. , 2010, Chinese medical journal.

[10]  J. Soriano,et al.  Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities , 2009, Thorax.

[11]  A. Buist,et al.  Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study , 2009, European Respiratory Journal.

[12]  A. Buist,et al.  Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  Shengming Liu,et al.  Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. , 2007, American journal of respiratory and critical care medicine.

[14]  D. Mannino,et al.  International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.

[15]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[16]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[17]  R. West,et al.  Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample , 2006, Thorax.

[18]  D. Mannino,et al.  Global burden of COPD: systematic review and meta-analysis , 2006, European Respiratory Journal.

[19]  R. Collins,et al.  Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC). , 2005, International journal of epidemiology.

[20]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[21]  Fei Xu,et al.  Prevalence of physician-diagnosed COPD and its association with smoking among urban and rural residents in regional mainland China. , 2005, Chest.

[22]  G. Viegi,et al.  Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.

[23]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[24]  M. Chan-yeung,et al.  The prevalence of asthma and asthma-like symptoms among adults in rural Beijing, China , 2002, European Respiratory Journal.

[25]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[26]  P. Enright,et al.  Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. , 2011, Chest.

[27]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.